157 related articles for article (PubMed ID: 7665657)
1. Determination of MICs for Mycobacterium avium-M. intracellulare complex in liquid medium by a colorimetric method.
Gomez-Flores R; Gupta S; Tamez-Guerra R; Mehta RT
J Clin Microbiol; 1995 Jul; 33(7):1842-6. PubMed ID: 7665657
[TBL] [Abstract][Full Text] [Related]
2. Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulation.
Gomez-Flores R; Hsia R; Tamez-Guerra R; Mehta RT
Antimicrob Agents Chemother; 1996 Nov; 40(11):2545-9. PubMed ID: 8913461
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
Huang CC; Wu MF; Chen HC; Huang WC
J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis.
Mehta RT; Keyhani A; McQueen TJ; Rosenbaum B; Rolston KV; Tarrand JJ
Antimicrob Agents Chemother; 1993 Dec; 37(12):2584-7. PubMed ID: 8109920
[TBL] [Abstract][Full Text] [Related]
5. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
6. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
7. French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complex.
Rastogi N; Bauriaud RM; Bourgoin A; Carbonnelle B; Chippaux C; Gevaudan MJ; Goh KS; Moinard D; Roos P
Antimicrob Agents Chemother; 1995 Mar; 39(3):638-44. PubMed ID: 7793865
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of Mycobacterium avium and Mycobacterium intracellulare to various antibacterial drugs.
Tomioka H; Sato K; Saito H; Yamada Y
Microbiol Immunol; 1989; 33(6):509-14. PubMed ID: 2770562
[TBL] [Abstract][Full Text] [Related]
9. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.
Mehta RT
Antimicrob Agents Chemother; 1996 Aug; 40(8):1893-902. PubMed ID: 8843300
[TBL] [Abstract][Full Text] [Related]
10. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Jul; 66(7):489-92. PubMed ID: 1890791
[TBL] [Abstract][Full Text] [Related]
11. N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
Klopman G; Fercu D; Renau TE; Jacobs MR
Antimicrob Agents Chemother; 1996 Nov; 40(11):2637-43. PubMed ID: 8913479
[TBL] [Abstract][Full Text] [Related]
12. Use of potassium tellurite for rapid-drug susceptibility testing of Mycobacterium avium complex.
Afghani B; Fujiyama D
J Investig Med; 2001 May; 49(3):292-6. PubMed ID: 11352188
[TBL] [Abstract][Full Text] [Related]
13. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
14. Difference in drug susceptibility distribution and clinical characteristics between
Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
[No Abstract] [Full Text] [Related]
15. Comparative in-vitro activity of Bay y 3118, a new quinolone, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Sirgel FA; Venter A; Heilmann HD
J Antimicrob Chemother; 1995 Feb; 35(2):349-51. PubMed ID: 7759400
[No Abstract] [Full Text] [Related]
16. Comparison of the activity of fluoroquinolones against Mycobacterium avium in cell-free systems and a human monocyte in-vitro infection model.
Shiratsuchi H; Jacobs MR; Pearson AJ; Venkataprasad N; Klopman G; Ellner JJ
J Antimicrob Chemother; 1996 Mar; 37(3):491-500. PubMed ID: 9182106
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of patients with bacteraemia caused by Mycobacterium avium complex species and antimicrobial susceptibility of the isolates at a medical centre in Taiwan, 2008-2014.
Lee MR; Chien JY; Huang YT; Liao CH; Shu CC; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2017 Jul; 50(1):35-40. PubMed ID: 28478210
[TBL] [Abstract][Full Text] [Related]
18. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method.
Tomioka H; Saito H; Fujii K; Sato K; Hidaka T
Antimicrob Agents Chemother; 1993 Jan; 37(1):67-70. PubMed ID: 8431020
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.
Yajko DM; Sanders CA; Nassos PS; Hadley WK
Antimicrob Agents Chemother; 1990 Dec; 34(12):2442-4. PubMed ID: 2088204
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan.
Yamaba Y; Ito Y; Suzuki K; Kikuchi T; Ogawa K; Fujiuchi S; Hasegawa N; Kurashima A; Higuchi T; Uchiya KI; Watanabe A; Niimi A
J Infect Chemother; 2019 Dec; 25(12):995-1000. PubMed ID: 31239192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
